H.C. Wainwright Sticks to Their Hold Rating for CytomX Therapeutics (CTMX)
Express News | CytomX Therapeutics Announces First Patient Dosed With Cx-801, a Dually-Masked Interferon-Alpha 2B Probody®, in a Phase 1 Study in Patients With Solid Tumors
CytomX Therapeutics Announces First Patient Dosed With CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients With Solid Tumors
CytomX Therapeutics to Present at Upcoming September Investor Conferences
Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and CytomX Therapeutics (CTMX)
HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics